In recent years, the role of multi-gene NGS-based plasma ctDNA analysis has been further emphasized in clinical guidelines, marking a significant shift from single-gene testing (e.g., EGFR mutation) to a broader and more comprehensive approach for advanced NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.